UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington,WASHINGTON, D.C. 20549

FORM 10-Q

[X]☒ QUARTERLY REPORT PURSUANT TOUNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended:ended February 28,November 30, 2022

OR

[☐] TRANSITION REPORT PURSUANT TOUNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Periodtransition period from ___________ to____________

Commission File Number: 333-213009

CANNABIS SUISSE CORP.

(Exact name of registrant as specified in its charter)_________ to ________

Commission file number: 333-213009

6607 Clara St #270, Bell Gardens, CA9020110 North Newman Street, Suite A

Jacksonville, FL 32202

Phone: (502) 2082098

E-mail: manage@cannabissuissecorp.com(904) 595 5820

(Address, including zip code, and telephone number,

Includingincluding area code, of registrant’s principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check markcheckmark whether the registrant (1) has filed all reports required to be filed by sectionSection 13 or 15(d) of the Securities Exchange Act of 1934 during the pastpreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes Yes☒ (X) No ( )☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ( ) No☒ (X)No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,”filer”, “accelerated filer”, “non-accelerated filer”, “emerging growth company” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B)13(a) of the SecuritiesExchange Act. ()☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ( ) No☐ (X)No ☒

As of April 14, 2022,February 8, 2023, there were 36,491,97544,254,938 shares outstanding of the registrant’s common stock.

i

TABLE OF CONTENTS

2

3

ii

PART I –- FINANCIAL INFORMATION

Item 1. Financial statementsstatements.

The accompanying interim consolidated financial statements of Cannabis Suisse Corp. (the “Company”) should be read in conjunction with the 10-K that was filed with the United States Securities and Exchange Commission (the “SEC”). The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, since they are interim statements, the accompanying consolidated financial statements do not include all the information and notes required by GAAP for complete financial statement presentation. In the opinion of management, the interim consolidated financial statements reflect all adjustments (consisting of normal, recurring adjustments) that are necessary for a fair presentation of the financial position, results of operations, and cash flows for the interim periods presented. Interim results are not necessarily indicative of results for a full year.

In the opinion of management, the consolidated financial statements contain all material adjustments, consisting only of normal adjustments considered necessary to present fairly the financial condition, results of operations, and cash flows of the Company for the interim periods presented.

4

CANNABIS SUISSE CORP.

CONSOLIDATED BALANCE SHEETS

The accompanying notes are an integral part of these statements.

5

CANNABIS SUISSE CORP.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)

The accompanying notes are an integral part of these statements.

6

CANNABIS SUISSE CORP.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT (UNAUDITED)BALANCE SHEETS

The accompanying notes are an integral part of these unaudited financial statements.

CANNABIS SUISSE CORP.

STATEMENTS OF OPERATIONS

(unaudited)

7

CANNABIS SUISSE CORP.

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

The accompanying notes are an integral part of these unaudited financial statements.

CANNABIS SUISSE CORP.

STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR THE SIX MONTHS ENDED NOVEMBER 30, 2021 AND 2022

(unaudited)

The accompanying notes are an integral part of these unaudited financial statements.

CANNABIS SUISSE CORP.

STATEMENTS OF CASH FLOWS

(unaudited)

8

The accompanying notes are an integral part of these unaudited financial statements.

CANNABIS SUISSE CORP.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(unaudited)

NOTE 1 – - ORGANIZATION AND NATURE OF BUSINESS

The Company is engaged in the business of production of OTC (over-the-counter) products - for example CBD oils, retail branded cigarettes and also some health-related supplements. We use various distribution channels for various types of customers. The Company’s products can be sold to both corporate customers and individual clients.

In late May 2022, the former shareholder signed an agreement to sell all his stock to Mr. Scott McAlister. The stock purchase agreement was closed in early June 2022.

NOTE 2 – -SUMMARY OF SIGNIFCANTSIGNIFICANT ACCOUNTING POLICIES

The financial information furnished herein reflects all adjustments, consisting of normal recurring items that, in the opinion of management, are necessary for a fair presentation of the Company's financial position, results of operations and cash flows for the interim periods. The results of operations for the ninesix months ended February 28,November 30, 2022 are not necessarily indicative of the results to be expected for the year ending May 31, 2022.2023.

The information included in this Form 10-Q should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended May 31, 2021.2022.

Basis of presentation and consolidation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, (GAAP). The Company’s year-end is May 31. The consolidated financial statements include the accounts of the Company and its former wholly-owned subsidiary, Cannabis Suisse LLC, through the date of disposal (see Note 4). All significant inter-company accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Cash and CashEquivalents Equivalents

The Company considersThe Company considers all highly liquid investments with the original maturities of three months highly liquid investments with the original maturities of three months or less less to be cash equivalents.cash equivalents. The Company had $38,339 in its escrow account and $0 of cash and cash equivalents as of February 28,November 30, 2022 and May 31, 2021,2022, respectively. The funds in the escrow account can be released for the company’s operations without restriction.

Accounts Receivable

The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluationreceivables. The allowance for losses was $0 as of the collectability of the accountsNovember 30, 2022, and prior loss experience.May 31, 2022.

InventoriesInventories

Inventories are stated at the lower of cost or market. The Company had $0 and $1,734 in inventory as of February 28,November 30, 2022 and May 31, 2021,2022, respectively. The Company also determines a reserve for excess and obsolete inventory based on historical usage, and projecting the year in which inventory will be consumed into a finished product. The valuation of inventories requires management to make significant assumptions, including the assessment of market value by inventory category considering historical usage, future usage and market demand for their products, and qualitative judgments related to discontinued, slow moving and obsolete inventories. The Company had $0 in reserve for excess and obsolete inventory as of February 28,November 30, 2022 and May 31, 2021,2022, respectively.

9

CANNABIS SUISSE CORP.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(unaudited)

Property and equipment

Property and equipment are carried at cost less accumulated depreciation. Depreciation is provided over the assets’ estimated useful lives, using the straight-line method. Estimated useful lives of the plant and equipment are as follows:

The cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the consolidated statements of operations and comprehensive loss.operations. The cost of maintenance and repairs is charged to the consolidated statements of operations and comprehensive loss as incurred, whereas significant renewals and betterments are capitalized.

Leases

The Company adopts the accounting for leases under Accounting Standards Codification (ASC) 842 Lease Accounting and determines if an arrangement is a lease or contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, and operating lease liabilities (current and non-current) in the Company’s balance sheets.

ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses the incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

Impairment of Long-Lived Assets

The Company evaluates the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Our evaluation is based on an assessment of potential indicators of impairment, such as an adverse change in the business climate that could affect the value of an asset, current or forecasted operating or cash flow losses that demonstrate continuing losses associated with the use of an asset, and a current expectation that, more likely than not, an asset will be disposed of before the end of its previously estimated useful life. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.

During the ninesix months ended February 28,November 30, 2022, and 2021, the Company recognized an impairment of intangibleslong-lived assets in the amount of $0, respectively.

Fair Value of Financial Instruments

Accounting Standards Codification (“ASC”)ASC 820 Fair Value Measurements and Disclosures establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.

These tiers include:

Level 1:defined as observable inputs such as quoted prices in active markets; 

Level 2:defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and 

Level 3:defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. 

The carrying value of the Company’s cash, other current assets, accounts payable, accrued expenses and advances from related parties approximates its fair value due to their short-term maturity. The Company has derivatives that are measured at level 3. The derivatives may require appropriate valuation adjustments that a market participant would require to arrive at fair value.

10

CANNABIS SUISSE CORP.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(unaudited)

Derivatives

Derivative instruments are recognized in the Consolidated Financial Statementsfinancial statements at fair value. Where the Company has entered into master netting agreements with counterparties, the derivative positions are netted by counterparties and are reported accordingly in other assets or other liabilities. Changes in the fair value of derivative instruments are recognized in earnings each period, unless the derivative is designated and qualifies as a cash flow or net investment hedge.

Income Taxes

The Company accounts for its income taxes in accordance with ASC 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Update (ASU) 2014-09, “Revenue from contracts with customers” customers(Topic (Topic 606). Revenue is recognized when a customer obtains control of promised goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the considerations that the Company expects to receive in exchange for those goods.

The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

The Company only applies the five-step model to contracts when it is probablyprobable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon delivery. For our new customers, the Company generally requires orders placed to be backed by advances or deposits. In general, the Company provides payment terms between 30 to 60 days following receiving of goods.

CostCost of Goods Sold

Cost of goods sold includes direct costs of selling items, direct labor cost, rent expense and electricity.

Basic Income (Loss) Per Share

The Company computes income (loss) per share in accordance with ASC 260 Earnings per Share.Share. Basic loss per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted income (loss) per share gives effect to all dilutive potential common shares outstanding during the period.  Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. As of February 28, 2022November 30, and May 31, 2021,2022, there were no potentially dilutive debt or equity instruments issued or outstanding.

Foreign Currency Translation

Assets and liabilities of the Company’s Swiss subsidiary are translated from Swiss francs to United States dollars at exchange rates in effect at the balance sheet date. Income and expenses are translated at average exchange rates during the period. The translation adjustments for the reporting period are included in the Company’s consolidated statements of operations and comprehensive loss, and the cumulative effect of these adjustments are reported in the Company’s consolidated balance sheets as accumulated other comprehensive loss within stockholders’ deficit.

11

CANNABIS SUISSE CORP.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Recent Accounting Pronouncements

There have been no recent accounting pronouncements or changes in accounting pronouncements during the ninesix months ended February 28,November 30, 2022, that are of significance or potential significance to the Company.

CANNABIS SUISSE CORP.

NOTES TO THE FINANCIAL STATEMENTS

(unaudited)

NOTE 3 – - GOING CONCERN

The accompanying consolidated financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern. However, the Company had limited revenues and recurring losses as of February 28,November 30, 2022. The Company has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern.

Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses. The Company intends to position itself so that it will be able to raise additional funds through the capital markets. In light of management’s efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.

The impact of the COVID-19 pandemic has had, and is expected to continue to have, an adverse effect on our business and our financial results. COVID-19 pandemic has negatively affected global economy, disrupted consumer spending and global supply chains and created significant volatility and disruption of financial markets. The pandemic had and will continue to have an adverse effect on our business and financial performance. The extent of the impact of COVID-19, including the Company’s ability to execute its business strategies as planned, will depend on future developments, including the duration and severity of the pandemic, which are uncertain and cannot be predicted. The COVID-19 pandemic could also adversely affect its liquidity and ability to access the capital markets. Uncertainty regarding the duration of the COVID-19 pandemic may adversely impact its ability to raise additional capital, or require additional capital.

NOTE 4 - BUSINESS COMBINATION

On November 23, 2020, Cannabis Suisse Corp. (the “Transferor”), entered into an Asset Transfer Agreement with Cecillia Merige Jensen (the “Transferee”) and Cannabis Suisse LLC. In accordance with the terms of the Agreement, the Transferor transferred to the Transferee all its right, title and interest to one hundred percent (100%) of Cannabis Suisse LLC, including all its right, title and interest to one hundred percent (100%) of Grow Factory GmbH and the Transferee transferred and assigned to the Transferor 10,000,000 restricted shares of Cannabis Suisse Corp., free and clear of any and all liens and encumbrances. The above-mentioned Asset Transfer Agreement hereby revokes the effect of the Stock Transfer Agreement entered into with Cecillia Jensen on May 31, 2019, and the 10,000,000 shares were returned to the President of the Company to reinstate his ownership percentage pre-acquisition.

12

CANNABIS SUISSE CORP.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 5 – 4 - PROPERTY AND EQUIPMENT

Property and equipment:Equipment:

For the three months ended February 28,November 30, 2022 and 2021, the Company recognized depreciation expense in the amount of $543$1,061 and $679,$582, respectively. For the ninesix months ended February 28,November 30, 2022 and 2021, the Company recognized depreciation expense in the amount of $1,706$2,122 and $9,003,$1,164, respectively.

NOTE 6 – 5 - COMMITMENTS AND CONTINGENCIES

During the normal course of business, the Company may be exposed to litigation. When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with FASB ASC 450-20-50, Contingencies.Contingencies. The Company evaluates its exposure to the matter, possible legal or settlement strategies and the likelihood of an unfavorable outcome. If the Company determines that an unfavorable outcome is probable and can be reasonablereasonably estimated, it establishes the necessary accruals. As of February 28,November 30, 2022, the Company is not aware of any contingent liabilities that should be reflected in the financial statements.

NOTE 7 – 6 - RELATED PARTY TRANSACTIONS

The Company’sCompany’s former President, hasSuneetha Nandana Silva Sudusinghe, agreed to provide interest free advances, due on demand, to the Company up to $100,000. As of February 28,For the six months ended November 30, 2022, and May 31, 2021, Suneetha Nandana Silva Sudusinghe advanced to the Company $2,234$0 and $31,650, respectively.

In June 2022, the ownership changed, and the current major shareholder took the position of the president. For the six months ended November 30, 2022, and 2021, the current president advanced to the Company $1,209 and $0, respectively.

On January 19,In November 2022, Alain Parrik resignedthe Company issued a convertible note payable to the major shareholder in the amount of $135,000 to pay off the funds advanced from and the positionsoperating expenses paid by the shareholder. See Note 7 Convertible Notes Payable for terms and conditions.

As of November 30, and May 31, 2022, the balances of advances from related parties were $1,209 and $1,589, respectively.

In June 2022, the major stockholder made contributions of office equipment and furniture to the Company. The total value of the Chief Operating Officer and Director of the Company.

As of January 19, 2022 The Company has an outstanding debt to Alan Parrik. The amount of the debt is $85,000. The Agreement contains a provision that allows Alain Parrik to convert the debt to common stock at a fixed price of $0.005 per share after 3 - month period of lockup.

NOTE 8 – CONVERTIBLE NOTES PAYABLE

On December 1, 2020, Suneetha Nandana Silva Sudusinghe assigned SAPA Investments, LLC $10,000 of his loan to Cannabis Suisse Corp. The Agreement contains a provision that allows SAPA Investments, LLC to convert the loan to common stock at a 70%-discount to the market price at the time of conversion after a period of lockup of 30 days.

The original loan to Cannabis Suisse Corp. from Mr. Sudusinghecontributions was pursuant to Loan Agreement dated March 1, 2016 and Verbal Agreement dated April 2, 2019.$33,100.

On December 4, 2020 Suneetha Nandana Silva Sudusinghe assigned SAPA Group, LLC $10,000 of his loan to Cannabis Suisse Corp. The Agreement contains a provision that allows SAPA Group, LLC to convert the loan to common stock at a 70%-discount to the market price at the time of conversion after a period of lockup of 30 days.

The original loan to Cannabis Suisse Corp. from Mr. Sudusinghe was pursuant to Loan Agreement dated March 1, 2016 and Verbal Agreement dated April 2, 2019.

On December 7, 2020 Suneetha Nandana Silva Sudusinghe assigned GSS Group LLC $10,000 of his loan to Cannabis Suisse Corp. The Agreement contains a provision that allows GSS Group LLC to convert the loan to common stock at a 70%-discount to the market price at the time of conversion after a period of lockup of 30 days.

The original loan to Cannabis Suisse Corp. from Mr. Sudusinghe was pursuant to Loan Agreement dated March 1, 2016 and Verbal Agreement dated April 2, 2019.

On December 10, 2020 Suneetha Nandana Silva Sudusinghe assigned Noi Tech LLC $10,000 of his loan to Cannabis Suisse Corp. The Agreement contains a provision that allows Noi Tech LLC to convert the loan to common stock at a 70%-discount to the market price at the time of conversion after a period of lockup of 30 days.

13

CANNABIS SUISSE CORP.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(unaudited)

The original loan to Cannabis Suisse Corp. from Mr. Sudusinghe was pursuant to Loan Agreement dated March 1, 2016 and Verbal Agreement dated April 2, 2019.NOTE 7 - CONVERTIBLE NOTES PAYABLE

On April 1, 2021, Suneetha Nandana Silva Sudusinghe assigned Serhii Cherniienko $60,000 of his loan to Cannabis Suisse Corp. The Agreement contains a provision that allows Serhii Cherniienko to convert the loan to common stock at a fixed price of $0.01 per share. Beneficial conversion feature was $60,000. Of the $60,000, $30,000 was converted to equity in December 2021, and debt discountthe rest of $30,000 was $19,672.

The original loanassigned to Cannabis Suisse Corp. from Mr. Sudusinghe was pursuantOkie LLC. In November 2022, Okie LLC assigned the convertible note to Loan Agreement dated March 1, 2016 and Verbal Agreement dated April 2, 2019.Clifford Koschnick for consideration.

On April 15, 2021, Suneetha Nandana Silva Sudusinghe assigned Noi Tech LLC $30,000 of his loan to Cannabis Suisse Corp. The Agreement contains a provision that allows Noi Tech LLC to convert the loan to common stock at a fixed price of $0.01 per share. Beneficial conversion feature was $30,000 and debt$30,000. The note was assigned to Okie LLC with a $10,000 discount was $7,541.in May 2022. In November 2022, Okie LLC assigned the convertible note to Clifford Koschnick for consideration.

The original loanIn May 2022, Alain Parrik assigned his convertible note of $85,000 the Company owed him to Cannabis Suisse Corp. from Mr. Sudusinghe was pursuantOkie LLC. According to Loan Agreement dated March 1, 2016the note terms and Verbal Agreement dated April 2, 2019.

On December 1, 2021 Suneetha Nandana Silva Sudusinghe assigned Serghei Dumanov $12,000 of his loanconditions, the note can be converted to Cannabis Suisse Corp. The Agreement contains a provision that allows Serghei Dumanov to convert the loan to common stockshares at a fixed price of $0.005 per share. In November 2022, Okie LLC assigned the convertible note to Scott McAlister for consideration.

In November 2022, the Company issued a convertible promissory note in the principal of $135,000 to the Company’s CEO for funds he has advanced the Company for expenses. The original loan to Cannabis Suisse Corp. from Mr. Sudusinghe was pursuant to Loan Agreement dated March 1, 2016Note has a term of four years, the interest rate is 12% and Verbal Agreement dated April 2, 2019.

On February 1, 2022 Suneetha Nandana Silva Sudusinghe assigned Galina Balan $18,500 of his loan to Cannabis Suisse Corp. The Agreement contains a provision that allows Galina Balan to convert the loan to common stock at a fixedconversion price of $0.005is $0.04 per share.

The Company’s convertible promissory notes gave rise to derivative financial instruments. The notes embodied certain terms and conditions that were not clearly and closely related to the host debt agreement in terms of economic risks and characteristics. These terms and features consist of the embedded conversion option.NOTE 8 - STOCKHOLDERS’ EQUITY

The following tables summarize the components of the Company’s derivative liabilities and linked common shares as of February 28, 2022 and 2021 and the amounts that were reflected in income related to derivatives for the period ended:

14

CANNABIS SUISSE CORP.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The following table summarizes the effects on the Company’s gain (loss) associated with changes in the fair values of the derivative financial instruments by type of financing for the three months ended February 28, 2022 and 2021:

The following table summarizes the effects on the Company’s gain (loss) associated with changes in the fair values of the derivative financial instruments by type of financing for the nine months ended February 28, 2022 and 2021:

Current accounting principles that are provided in ASC 815 - Derivatives and Hedging require derivative financial instruments to be classified in liabilities and carried at fair value with changes recorded in income. The Company has selected the Monte Carlo Simulation Model, which approximates the Monte Carlo Simulations, valuation technique to fair value the embedded derivative because it believes that this technique is reflective of all significant assumption types, and ranges of assumption inputs, that market participants would likely consider in transactions involving embedded derivatives. Such assumptions include, among other inputs, interest risk assumptions, credit risk assumptions and redemption behaviors in addition to traditional inputs for option models such as market trading volatility and risk-free rates. The Binomial Lattice Model technique is a level three valuation technique because it requires the development of significant internal assumptions in addition to observable market indicators. For instruments in which the time to expiration has expired, the Company has utilized the intrinsic value as the fair value. The intrinsic value is the difference between the quoted market price on the valuation date and the applicable conversion price.

Significant inputs and results arising from the Monte Carlo Simulation process are as follows for the embedded derivatives that have been bifurcated from the convertible notes and classified in liabilities:

15

CANNABIS SUISSE CORP.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The following table reflects the issuances of embedded derivatives and changes in fair value inputs and assumptions related to the embedded derivatives as of February 28, 2022 and May 31, 2021.

NOTE 9 – REPORTABLE SEGMENTS

The Company follows segment reporting in accordance with ASC Topic 280, Segment Reporting. As a result of the business combination with Cannabis Suisse LLC in May 2019, the Company has changed its operating segments to consist of the Cannabis Suisse LLC segment and the Cannabis Suisse Corp segment. After the Cannabis Suisse LLC business combination, the Company's CEO began assessing performance and allocating resources based on the financial information of these two reporting segments.

The Cannabis Suisse LLC segment is involved in cannabis cultivation and distribution in Switzerland of recreational tobacco products and medical CBD oils. On November 23, 2020, Cannabis Suisse LLC and Cannabis Suisse Corp canceled their acquisition by Asset Transfer Agreement.

Cannabis Suisse Corp is engaged in the development of its business activities by conquering the USA market of CBD products since November 2020.

16

CANNABIS SUISSE CORP.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Net revenue by reporting segment for the three and nine months ended February 28, 2022 and 2021, is as follows:

Gross profit by reporting segment for the three and nine months ended February 28, 2022 and 2021, is as follows:

Assets by reporting segment as of February 28, 2022 and May 31, 2021, is as follows:

NOTE 10 – STOCKHOLDERS’ EQUITY

On March 17, 2021, the Board of Directors, along with the majority stockholder, resolved that the 5,000,000 preferred shares with voting rights of 1 to 10 shall be issued to Suneetha Nandana Silva Sudusinghe in exchange for 5,000,000 common shares that Suneetha Nandana Silva Sudusinghe owned previously.

The 5,000,000 preferred shares were issued on July 21, 2021.

NOTE 11 – INCOME9 - INCOME TAXES

The Company adopted the provisions of uncertain tax positions as addressed in ASC 740-10-65-1. As a result of the implementation of ASC 740-10-65-1, the Company recognized no increase in the liability for unrecognized tax benefits.

The Company has no tax position at February 28,November 30, 2022 for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. No such interest or penalties were recognized during the periodperiods presented. The Company had no accruals for interest and penalties at February 28,November 30, 2022. The Company’s utilization of any net operating loss carryforward may be unlikely as a result of its intended activities.

The valuation allowance at February 28,November 30, 2022 was $235,312.$176,548. The net change in valuation allowance for the ninesix months ended February 28,November 30, 2022, and for the year ended May 31, 20212022, was $51,593$26,088 and $88,068,$33,259, respectively. In assessing the realizabilityreliability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment.

17

CANNABIS SUISSE CORP.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of February 28, 2022November 30 and May 31, 2021.2022. All tax years since inception remains open for examination only by taxing authorities of US Federal and state of Nevada.

The Company has a net operating loss carryforward for tax purposes totaling $1,120,535$840,703 at February 28, 2022, expiringNovember 30, 2022. According to current tax laws, the losses prior to 2018 can carryforward 20 years, and the losses in 2018 or later can

CANNABIS SUISSE CORP.

NOTES TO THE FINANCIAL STATEMENTS

(unaudited)

carryforward indefinitely. The Company had losses of $43,526 prior to 2018 which can carryforward through fiscal year 2036. The losses of $797,177 in years of 2018 and later will carryforward indefinitely. There is a limitation on the amount of taxable income that can be offset by carryforwards after a change in control (generally greater than a 50% change in ownership).

The components of the Company’s deferred tax asset and reconciliation of income taxes computed at the new statutory rate of 21% to the income tax amount recorded as of February 28,November 30, 2022 and May 31, 20212022 are as follows:

The change in the valuation allowance during the nine months ended February 28, 2022 and year ended May 31, 2021 was $51,593 and $88,068, respectively.

NOTE 12 – 10 - SUBSEQUENT EVENTS

In accordance with SFASFASB 165 (ASC 855), Subsequent Events, the Company has analyzed its operations subsequent to February 28,November 30, 2022 to the date these consolidated financial statements were issued, and has determined that it does not have any material subsequent events to disclose.disclose in these financial statements except the following:

On January 11, 2023, the Company issued 3,600,000 restricted shares at $0.04 per share to a consultant for services. The value of the 3,600,000 shares issued is $144,000.

In February 2023, the Company signed a lease to rent the office at 10 Newman Street, Jacksonville, FL 32202, with 10 N Newnan LLC, a related party owned by our CEO. The lease commencement date is February 1, 2023 and the lease term is thirty-six months. Based on the criteria and according to ASC 842, the Right-of-Use (ROU) asset is $194,758, and the lease liability and lease commitment is also the same amount, respectively. The monthly base rental payment is $6,469, and the Company has the option to pay all or portion of the rent in shares of its common stock.

In February 2023, the Company signed a lease to rent the property at 2652 Blanding Blvd, Jacksonville, FL 32210, with 2600 Blanding Blvd., LLC, a related party Owned by our CEO. The lease commencement date is February 1, 2023 and the lease term is thirty-six months. Based on the criteria and according to ASC 842, the Right-of-Use (ROU) asset is $135,833, and the lease liability and lease commitment is also the same amount, respectively. The monthly base rental payment is $5,000 with incentives of free-rent for the first three months, and the Company has the option to pay all or portion of the rent in shares of its common stock.

In February 2023, the Company signed a sub-lease as the lessor to rent a portion of the property at 2652 Blanding Blvd to a third party private company. The monthly rent is $2,500 which will bring rental revenue of $30,000 annually. The term of the sub-lease is one year from February 2023 to January 2024.

18

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This quarterly report and other reports filed by Cannabis Suisse Corp. (Formerly Geant Corp.)  (“we,” “us,” “our,” or the “Company”), from time to time contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and assumptions made by Company’s management. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used in the filings, the words “anticipate”, “believe”, “estimate”, “expect”, “future”, “intend”, “plan” or the negative of these terms and similar expressions as they relate to the Company or the Company’s management identify forward-looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). These accounting principles require us to make certain estimates, judgments, and assumptions. We believe that the estimates, judgments, and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments, and assumptions are made. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates.

In General

Cannabis Suisse Corp. utilizes Swiss4Life as its retail brand for online selling. At this stage, Cannabis Suisse Corp. offers the following products:

Cannabis Suisse Corp. has initiated development of a newdeveloped an IT product called Cannabis Life. It is a mobile application based on an AI-chatbot that will have access to the most up-to-date information and find out data about companies and brands that sell seeds, cannabis types, etc.

Cannabis Life is an innovative way of searching and learning any cannabis related data. Using the most relevant sources of today, the app will keep its users up with the trends and tendencies of the cannabis industry. Communicating with the chatbot will be as smooth as it would be with a real human being thus giving users additional immersion into the learning process.

In May 2022, a change in control took place that was effective in June 2022. As a result we had no operations and were no longer in any aspect of the cannabis industry. Since the change in control we are continuing to lay the groundwork for our business operations. In January 2023, we entered into a lease for a commercial building. We also sublet a portion of the building to an unrelated party. The lease is with an entity owned by our CEO. Initially, we intend to pay the lease amount with shares of our common stock and collect the rent from the sublease to use in our operations.

Research and Development Expenditures

We have not incurred any research expenditures since our incorporation.

Bankruptcy or Similar Proceedings

There has been no bankruptcy, receivership or similar proceeding.

Employees; Identification of Certain Significant Employees

Other than our officers and directors, weWe currently do not have any employees. Our CEO/CFO acts as a consultant to the Company.

Results of Operations for the three and nine months ended February 28,November 30, 2022, and 2021:

Revenue and Cost of Goods Sold

19

For the three months ended February 28, 2022 andNovember 30, 2021, the Company has not generated any revenue.

For the nine months ended February 28, 2021, the Company generated total revenue of $50,850 from selling products to the customer. The cost of goods sold for the nine months ended February 28, 2021, was $102,648.

For the nine months ended February 28, 2022, the Company generated total revenue of $7,770 from selling products to the customers. The cost of goods sold for the ninethree months ended February 28,November 30, 2021 was $1,734.

For the three months ended November 30, 2022, the Company generated total revenue of $0 from selling products to the customers. The cost of goods sold for the three months ended November 30, 2022 was $0.

For the six months ended November 30, 2021, the Company generated total revenue of $7,770 from selling products to the customers. The cost of goods sold for the six months ended November 30, 2021 was $1,734.

For the six months ended November 30, 2022, the Company generated total revenue of $0 from selling products to the customers. The cost of goods sold for the six months ended November 30, 2021 was $0.

The decrease in revenues and cost of goods sold is a result ofdue to the separation of Cannabis Suisse LLCfact that the Company stopped its operations late in November 2020.the year ended May 31, 2022.

Operating expenses

Total operating expenses for the three months ended February 28,November 30, 2021, were $58,494.$47,387. The operating expenses for the three months ended February 28,November 30, 2021, included professional fees of $4,405;$4,136; depreciation expense of $679;$582; software development costs of $6,487 and general and administrative expenses of $53,410.$36,182.

Total operating expenses for the three months ended February 28,November 30, 2022, were $41,124.$29,375. The operating expenses for the three months ended February 28,November 30, 2022, included professional fees of $3,918;$25,200; depreciation expense of $543$1,061 and general and administrative expenses of $36,663.$3,114.

TotalThe decrease of $18,012 in operating expenses forwas mainly due to the nine months ended February 28, 2021 were $264,715. The operatingdecrease of $33,068 of administrative expenses, for the nine months ended February 28, 2021, includedalthough there was an increase in professional fees of $34,566; depreciation expense of $9,003; and general and administrative expenses of $221,146.$21,064 in professional fees.

Total operating expenses for the ninesix months ended February 28, 2022,November 30, 2021, were $140,425.$99,301. The operating expenses for the ninesix months ended February 28, 2022,November 30, 2021, included professional fees of $22,304;$18,386; depreciation expense of $1,706; $1,164; software development costs of $6,487 and general and administrative expenses of $109,928.$73,264.

Total operating expenses for the six months ended November 30, 2022, were $123,554. The operating expenses for the six months ended November 30, 2022, included professional fees of $99,861; depreciation expense of $2,122 and general and administrative expenses of $21,571.

The decreaseincrease of $24,253 in operating expenses is mainly related to the increase of professional fees of $81,475, although there was in decrease of general and administrative expenses and depreciation expense andof $51,693. The increase of the professional fees for the six months ended November 30, 2022 was due to the separationownership change in June 2022 with more professional services needed for the increase of Cannabis Suisse LLC inregulatory filings and related legal services. Meanwhile the decrease of the administrative expenses was because there were no payroll expenses after the ownership change. The payroll expenses were the major portion of the administrative expenses for the six months ended November 2020.30, 2021.

Changes in Fair Value of Derivatives

The changes in fair value of derivatives for the three months ended February 28,November 30, 2022 and 2021, was $(938)$0 and $10,981,$1,395, respectively. The reason the fair value change of the derivatives was $0 because the related debt instruments were converted or extinguished before May 31, 2022.

The changes in fair value of derivatives for the ninesix months ended February 28,November 30, 2022 and 2021, was $902$0 and $10,981,$1,841, respectively. The reason the fair value change of the derivatives was $0 is the same reason as explained above.

Other expenses

Total other expenses for the three months ended February 28,November 30, 2022 and 2021 were $792$675 and $33,131. $33,224. The other expenses for the three months ended February 28,November 30, 2022, included the interest expense of $792 ($33,131 as of February 28, 2021).

Total other expenses for the nine months ended February 28, 2022 and 2021, were $112,195 and $33,131. $675. The other expenses for the ninethree months ended February 28, 2022,November 30, 2021, included interest expense of $63,579 ($33,131 as of February 28, 2021)$17,541 and net loss on extinguishment of debt of $48,616 ($0 as$15,683.

Total other expenses for the six months ended November 30, 2022 and 2021 were $675 and $111,403. The other expenses for the six months ended November 30, 2021, included interest expense of February 28, 2021).$62,787 and net loss on extinguishment of debt of $48,616.

The increasedecrease in other expenses is related tofor the issuancethree and six month ended November 30, 2022, was that there were no significant interest expenses and loss on extinguishment of convertible notesdebt as there were in the three and six months ended November 30, 2021.

20

Net Loss

The net loss for the three months ended February 28,November 30, 2022 and 2021 was $42,854$30,050 and $80,644,$73,180, respectively.

The net loss for the ninesix months ended February 28,November 30, 2022 and 2021 was $245,682$124,229 and $338,663,$202,827, respectively.

Comprehensive Loss

The comprehensive loss for the three months ended February 28, 2022 and 2021 was $0 and $0, respectively.

The comprehensive loss for the nine months ended February 28, 2022 and 2021 was $0 and $8,478, respectively.

The decrease in comprehensive loss is related to decrease in foreign currency translation adjustment after the separation of Cannabis Suisse LLC in November 2020.

Liquidity and Capital Resources and Cash Requirements

As of February 28,November 30, 2022, the Company had cash of $0.$38,339. Furthermore, the Company had a working capital deficit of $309,165.$122,107.

During the ninesix months ended February 28,November 30, 2022 and 2021, the Company used $32,734$96,281 and $89,933$31,650 of cash in operating activities respectively. The change in cash used in operating activities is related to the decrease in net loss, depreciation, accounts receivable, accrued wages, and advances from customersexpenses, and the reductionincrease in depreciation and accounts payable, accrued expenses, and VAT tax receivable.payable.

During the ninesix months ended February 28,November 30, 2022 and 2021, the Company had $0 of cash in investing activities.

During the ninesix months ended February 28,November 30, 2022 and 2021, the Company was provided $32,734$134,620 and $89,928$31,650 of cash in financing activities respectively, which mainly came from advances from related convertible debt, bank indebtedness and issue of shares.party.

In its audited consolidated financial statements as of May 31, 2021,2022, the Company was issued a “going concern” opinion, meaning that there is substantial doubt we can continue as an on-going business for the next twelve months unless we obtain additional capital. Our only sources for cash at this time are investments by others, selling our products and loans from our director. We must raise cash to implement our plan and stay in business.

Management believes that current trends toward lower capital investment in start-up companies pose the most significant challenge to the Company’s success over the next year and in future years. Additionally, the Company will have to meet all the financial disclosure and reporting requirements associated with being a public reporting company. The Company’s management will have to spend additional time on policies and procedures to make sure it is compliant with various regulatory requirements, especially that of Section 404 of the Sarbanes-Oxley Act of 2002. This additional corporate governance time required of management could limit the amount of time management has to implement is business plan and impede the speed of its operations.

Limited operating history; need for additional capital

There is no historical financial information about us upon which to base an evaluation ofWe will rely on funds from our performance.operations and advances from our CEO in the near future. We are in a start-up stage of operations and have generated limited revenues since inception. We cannot guarantee that we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources and possible cost overruns due to price and cost increases in services and products.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

21

Related Party Transactions

There are two signed loan agreements between Cannabis Suisse Corp. and the President/CEO and a Director of the Company,The Company’s former President, Suneetha Nandana Silva Sudusinghe. The CEOSudusinghe, agreed to loan the Loan Amountprovide interest free advances, due on demand, to the Company inup to $100,000. For the event of not raising a sufficient amount of funds from the offering in accordance to the Form S-1 registration statement of the Company; the director agreed to loan the Loan Amountsix months ended November 30, 2022, and 2021, Suneetha Nandana Silva Sudusinghe advanced to the Company on demand$0 and $31,650, respectively.

In June 2022, the ownership changed, and the current major shareholder took the position of the Company;president. For the six months ended November 30, 2022, and 2021, the current president advanced to the Company will conduct$1,209 and $0, respectively.

In November 2022, the repaymentsCompany issued a convertible note payable to the major stockholder/CEO in the amount of all amounts$135,000 to pay off the funds advanced from and the operating expenses paid from the major shareholder. See Note 7 Convertible Notes Payable for terms and conditions.

As of November 30, and May 31, 2022, the balances of advances from related parties were $1,209 and $1,589, respectively. Subsequent to the period in January 2023, we entered into a lease for a commercial building with an entity owned by our CEO.  The lease is for two years.  Monthly payments are $12,916.  We also entered into a sublease for a portion of the Director’s loan accordinglybuilding with monthly payments of $4,500.  We have to option of paying the lease amount in cash or shares of our common stock. Initially, we intend to pay in common stock.

In February 2023, the Company signed a lease to rent the office at 10 Newman Street, Jacksonville, FL 32202, with 10 N Newnan LLC, a related party owned by our CEO. The lease commencement date is February 1, 2023 and the lease term is thirty-six months. Based on the criteria and according to ASC 842, the Right-of-Use (ROU) asset is $194,758, and the lease liability and lease commitment is also the same amount, respectively. The monthly base rental payment is $6,469, and the Company has the option to pay all or portion of the rent in shares of its common stock.

In February 2023, the Company signed a lease to rent the property at 2652 Blanding Blvd, Jacksonville, FL 32210, with 2600 Blanding Blvd., LLC, a related party Owned by our CEO. The lease commencement date is February 1, 2023 and the lease term is thirty-six months. Based on the criteria and according to ASC 842, the Right-of-Use (ROU) asset is $135,833, and the lease liability and lease commitment is also the same amount, respectively. The monthly base rental payment is $5,000 with incentives of free-rent for the first three months, and the Company has the option to pay all or portion of the rent in shares of its common stock.

In February 2023, the Company signed a sub-lease as the lessor to rent portion of the property at 2652 Blanding Blvd to a third party private company. The monthly rent is $2,500 which will bring the rental revenue of $30,000 annually. The term of the sub-lease is one year from February 2023 to January 2024.

Due to the sequence of loans; the director will be repaid from revenues ofleases signed in February 2023, the Company when it starts to earn significant revenues; advanced Loan funds are non-interest bearing, securedcontinues its operating and payable upon demand.the balance sheets shown before and after signing the leases as follows: